Valneva and Serum Institute End Chikungunya Vaccine Collaboration

Valneva SE and Serum Institute of India (SII) have agreed to discontinue their license agreement for Valneva's chikungunya vaccine. This decision allows Valneva to regain full rights and control over the vaccine's supply chain and commercialization. The aim is to enhance access in high-risk regions affected by chikungunya, a mosquito-borne disease causing significant medical and economic burdens.

The partnership's termination aligns with Valneva's strategy, supported by a funding agreement with CEPI and the European Union. The company aims to accelerate vaccine delivery for low-and-middle-income countries by assuming direct oversight.